Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Research & Development (2019 - 2026)

C4 Therapeutics has reported Research & Development over the past 8 years, most recently at $24.6 million for Q1 2026.

  • For Q1 2026, Research & Development fell 9.11% year-over-year to $24.6 million; the TTM value through Mar 2026 reached $101.8 million, down 11.64%, while the annual FY2025 figure was $104.2 million, 5.78% down from the prior year.
  • Research & Development for Q1 2026 was $24.6 million at C4 Therapeutics, down from $25.0 million in the prior quarter.
  • Over five years, Research & Development peaked at $32.5 million in Q4 2024 and troughed at $22.5 million in Q1 2024.
  • A 5-year average of $27.9 million and a median of $28.3 million in 2023 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: skyrocketed 34.51% in 2022 and later dropped 23.16% in 2025.
  • Year by year, Research & Development stood at $30.7 million in 2022, then decreased by 0.85% to $30.4 million in 2023, then grew by 6.98% to $32.5 million in 2024, then dropped by 23.16% to $25.0 million in 2025, then decreased by 1.51% to $24.6 million in 2026.
  • Business Quant data shows Research & Development for CCCC at $24.6 million in Q1 2026, $25.0 million in Q4 2025, and $26.0 million in Q3 2025.